TrialWatch: Bavencio Shows Real Promise in Phase I Trial for Malignant Mesothelioma Patients

Feb 13, 2019 | Checkpoint Inhibitors, Malignant Mesothelioma,, Oncology, Positive Results

Malignant Mesothelioma,

Immuno-Oncology News’ Ines Martins reports Merck KGaA (operating as EMD Serono in the U.S.) and Pfizer’s jointly developed immune checkpoint inhibitor Bavencio (avelumab) shows durable clinical activity and long-term disease control among heavily pretreated malignant mesothelioma patients according to recent Phase I clinical trial information.  According to early data, the drug controlled the disease in 58% of patients, with 17% living without disease worsening for one year or longer. The findings were published in JAMA Oncology. The clinical trial was described as a Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications.

0 Comments

Pin It on Pinterest